Sera Prognostics (SERA) Competitors $2.38 +0.13 (+5.78%) Closing price 04:00 PM EasternExtended Trading$2.37 -0.01 (-0.63%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SERA vs. AGL, LFMD, VMD, XGN, CORBF, DCGO, EUDA, QIPT, BNR, and NAKAShould you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Agilon Health (AGL), LifeMD (LFMD), Viemed Healthcare (VMD), Exagen (XGN), Global Cord Blood (CORBF), DocGo (DCGO), EUDA Health (EUDA), Quipt Home Medical (QIPT), Burning Rock Biotech (BNR), and KindlyMD (NAKA). These companies are all part of the "healthcare" industry. Sera Prognostics vs. Its Competitors Agilon Health LifeMD Viemed Healthcare Exagen Global Cord Blood DocGo EUDA Health Quipt Home Medical Burning Rock Biotech KindlyMD Sera Prognostics (NASDAQ:SERA) and Agilon Health (NYSE:AGL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership. Do analysts recommend SERA or AGL? Agilon Health has a consensus target price of $3.07, suggesting a potential upside of 148.70%. Given Agilon Health's stronger consensus rating and higher probable upside, analysts clearly believe Agilon Health is more favorable than Sera Prognostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sera Prognostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Agilon Health 2 Sell rating(s) 12 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.11 Do institutionals and insiders hold more shares of SERA or AGL? 54.6% of Sera Prognostics shares are held by institutional investors. 13.5% of Sera Prognostics shares are held by insiders. Comparatively, 3.6% of Agilon Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, SERA or AGL? Sera Prognostics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Agilon Health has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Does the media refer more to SERA or AGL? In the previous week, Agilon Health had 10 more articles in the media than Sera Prognostics. MarketBeat recorded 12 mentions for Agilon Health and 2 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.83 beat Agilon Health's score of 0.12 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilon Health 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, SERA or AGL? Sera Prognostics has higher earnings, but lower revenue than Agilon Health. Sera Prognostics is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSera Prognostics$80K1,120.68-$32.90M-$0.85-2.80Agilon Health$6.06B0.08-$260.15M-$0.77-1.60 Is SERA or AGL more profitable? Agilon Health has a net margin of -5.35% compared to Sera Prognostics' net margin of -30,306.48%. Sera Prognostics' return on equity of -45.86% beat Agilon Health's return on equity.Company Net Margins Return on Equity Return on Assets Sera Prognostics-30,306.48% -45.86% -34.31% Agilon Health -5.35%-66.76%-17.47% SummaryAgilon Health beats Sera Prognostics on 9 of the 16 factors compared between the two stocks. Get Sera Prognostics News Delivered to You Automatically Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SERA vs. The Competition Export to ExcelMetricSera PrognosticsMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.66M$7.66B$5.73B$9.56BDividend YieldN/A2.70%4.53%4.08%P/E Ratio-2.8076.3830.4625.16Price / Sales1,120.6830.60392.5787.62Price / CashN/A24.2337.0358.50Price / Book1.0216.818.956.21Net Income-$32.90M$243.33M$3.26B$265.38M7 Day Performance5.78%-0.95%1.06%-1.13%1 Month Performance-18.49%0.99%4.31%-0.71%1 Year Performance-66.94%11.01%28.39%18.86% Sera Prognostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SERASera Prognostics1.0707 of 5 stars$2.38+5.8%N/A-68.1%$89.66M$80K-2.80120News CoveragePositive NewsAGLAgilon Health2.6487 of 5 stars$0.86-1.3%$4.08+373.0%-74.0%$362.04M$6.06B-1.121,076News CoverageAnalyst ForecastGap DownLFMDLifeMD2.6178 of 5 stars$6.72-1.5%$12.86+91.3%+19.0%$323.39M$212.45M-32.00230VMDViemed Healthcare2.1564 of 5 stars$7.29+2.7%N/A-7.0%$275.38M$224.26M21.441,179Positive NewsXGNExagen3.5678 of 5 stars$9.38+2.0%$11.25+19.9%+226.9%$202.43M$55.64M-10.54220Short Interest ↑CORBFGlobal Cord BloodN/A$1.35flatN/A-14.3%$164.09M$196.12M0.001,200DCGODocGo2.1446 of 5 stars$1.53-2.5%$3.56+132.7%-54.3%$160.11M$616.55M-8.054,407Analyst ForecastEUDAEUDA Health0.7685 of 5 stars$2.52-3.4%N/A-54.5%$96.98M$4.01M0.002Gap UpQIPTQuipt Home Medical3.3158 of 5 stars$2.12-0.5%$2.85+34.4%-17.0%$92.54M$245.91M-10.091,200Analyst ForecastBNRBurning Rock Biotech0.3672 of 5 stars$6.94+1.8%N/A+40.9%$73.39M$70.67M-3.671,390News CoverageUpcoming EarningsGap DownNAKAKindlyMDN/A$14.28+49.2%N/AN/A$72.79M$2.72M-16.60N/AHigh Trading Volume Related Companies and Tools Related Companies AGL Competitors LFMD Competitors VMD Competitors XGN Competitors CORBF Competitors DCGO Competitors EUDA Competitors QIPT Competitors BNR Competitors NAKA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SERA) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sera Prognostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access